InterventionsReview

Genetically engineered hypoimmunogenic iPSCs: Strategies and considerations for clinical applications

Fig. 1. Variety of CRISPR-Cas systems for genome editing in mammalian cells.
Open the figure at full size
Fig. 1. Variety of CRISPR-Cas systems for genome editing in mammalian cells.Variety of CRISPR-Cas systems for genome editing in mammalian cells.Choi et al.

Regenerative Therapy

The paper

Kyoto University

Regenerative Therapy · 19 Sep 2026

doi.org/10.1016/j.reth.2026.101172PubMed 42825016

More in Interventions